MX2018001723A - Conjugados farmaco-multiligando y usos de los mismos. - Google Patents

Conjugados farmaco-multiligando y usos de los mismos.

Info

Publication number
MX2018001723A
MX2018001723A MX2018001723A MX2018001723A MX2018001723A MX 2018001723 A MX2018001723 A MX 2018001723A MX 2018001723 A MX2018001723 A MX 2018001723A MX 2018001723 A MX2018001723 A MX 2018001723A MX 2018001723 A MX2018001723 A MX 2018001723A
Authority
MX
Mexico
Prior art keywords
drug conjugates
ligand drug
cell
payload
interacting molecules
Prior art date
Application number
MX2018001723A
Other languages
English (en)
Inventor
Liu Xiaodong
Robert Huang Baohua
Dai Jian
Wang Zhongbo
Xie Xueyuan
Hu Xinli
Original Assignee
Coherent Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Application filed by Coherent Biopharma filed Critical Coherent Biopharma
Publication of MX2018001723A publication Critical patent/MX2018001723A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen compuestos conjugados o sales farmacéuticamente aceptables de los mismos, sus composiciones farmacéuticas y métodos para usarlos. En términos particulares, en este documento se describen conjugados fármaco-multiligando, especialmente conjugados multiligando capaces de inducir endocitosis, así como sus composiciones farmacéuticas, métodos para usarlos en la administración de cargas efectivas a sujetos que lo necesiten y métodos para usarlos en el tratamiento contra enfermedades que incluyen, entre otras, cánceres, enfermedades inmunológicas, enfermedades cardiovasculares, enfermedades metabólicas y enfermedades neurológicas.
MX2018001723A 2015-08-11 2016-08-11 Conjugados farmaco-multiligando y usos de los mismos. MX2018001723A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2018001723A true MX2018001723A (es) 2018-05-17

Family

ID=57983917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001723A MX2018001723A (es) 2015-08-11 2016-08-11 Conjugados farmaco-multiligando y usos de los mismos.

Country Status (14)

Country Link
US (2) US11571480B2 (es)
EP (1) EP3334500B1 (es)
JP (3) JP6772199B2 (es)
KR (2) KR102301596B1 (es)
CN (3) CN108135881B (es)
AU (2) AU2016305703B2 (es)
CA (1) CA2987322C (es)
DK (1) DK3334500T3 (es)
ES (1) ES2877409T3 (es)
HK (1) HK1250634A1 (es)
MX (1) MX2018001723A (es)
RU (1) RU2722449C2 (es)
WO (1) WO2017025057A1 (es)
ZA (1) ZA201707464B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3716991A4 (en) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. TRPV6 INHIBITORS AND POLYTHERAPIES FOR THE TREATMENT OF CANCERS
CA3084092A1 (en) 2017-12-06 2019-06-13 Ontario Institute For Cancer Research (Oicr) Acyl hydrazone linkers, methods and uses thereof
EP3728273A4 (en) 2017-12-22 2021-12-29 Ontario Institute for Cancer Research (OICR) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
JP2022542560A (ja) * 2019-07-22 2022-10-05 パーデュー・リサーチ・ファウンデーション 線維芽細胞を標的とする多価作用物質、および使用方法
EP4047098A4 (en) * 2019-08-20 2023-06-07 EGI Tech (Shen Zhen) Co., Limited PROCEDURE FOR SEQUENCING POLYNUCLEOTIDS BASED ON OPTICAL SIGNAL DYNAMICS OF A LUMINESCENT LABEL AND SECONDARY LUMINESCENT SIGNAL
US20240058478A1 (en) * 2021-01-07 2024-02-22 Purdue Research Foundation Folate receptor-targeted conjugates, compositions, and delivery to the central nervous system
EP4360654A1 (en) * 2021-06-25 2024-05-01 Coherent Biopharma (Suzhou), Limited Ligand-drug conjugate and use thereof
EP4385498A1 (en) * 2021-09-08 2024-06-19 Coherent Biopharma (Suzhou), Limited Pharmaceutical preparation, preparation method therefor and use thereof
AU2022371507A1 (en) * 2021-10-19 2024-05-02 Coherent Biopharma (Suzhou) Limited Conjugate drug preparation, preparation method therefor and use thereof
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
KR101085784B1 (ko) * 2001-10-22 2011-11-25 더 스크립스 리서치 인스티튜트 인테그린 표적화 화합물
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
ES2717836T3 (es) 2003-12-05 2019-06-25 Arrogene Inc Sistema de administración de fármacos multifuncional a base de ácido polimálico
US20100166654A1 (en) 2004-12-03 2010-07-01 The Uab Research Foundation Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
CN103893778A (zh) 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
EP2073820A4 (en) * 2006-09-15 2014-07-16 Belrose Pharma Inc TARGETED POLYMER PRODRUGS WITH MULTIFUNCTIONAL CONNECTORS
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
JP2012509066A (ja) * 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド 核酸送達系のための放出可能接合体
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP2600900A4 (en) 2010-08-06 2014-11-19 Univ Illinois SUPRAMOLECULAR MULTIPLEX AGGREGATES FOR THE NONVIRAL OUTPUT OF GENETIC MATERIALS
US9744246B2 (en) 2011-06-06 2017-08-29 Starpharma Pty Ltd Macromolecules
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
WO2013170272A2 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
CA2890455A1 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
TR201905612T4 (tr) 2012-12-05 2019-05-21 Univ Heidelberg Ruprecht Karls Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları.
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
CN109316605B (zh) * 2014-01-20 2023-07-14 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN104667292B (zh) * 2015-02-02 2017-09-05 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
WO2016183359A1 (en) * 2015-05-12 2016-11-17 Blinkbio, Inc. Silicon based drug conjugates and methods of using same

Also Published As

Publication number Publication date
RU2722449C2 (ru) 2020-06-01
AU2016305703A1 (en) 2017-11-23
KR102464778B1 (ko) 2022-11-07
DK3334500T3 (da) 2021-06-21
JP6772199B2 (ja) 2020-10-21
AU2016305703B2 (en) 2019-07-25
CN111617250A (zh) 2020-09-04
AU2019240611B2 (en) 2021-09-09
JP2018529632A (ja) 2018-10-11
US11571480B2 (en) 2023-02-07
JP2021006549A (ja) 2021-01-21
EP3334500A1 (en) 2018-06-20
RU2018104266A3 (es) 2019-09-12
AU2019240611A1 (en) 2019-10-17
KR20200071152A (ko) 2020-06-18
RU2018104266A (ru) 2019-09-12
WO2017025057A1 (en) 2017-02-16
KR102301596B1 (ko) 2021-09-14
CN111617250B (zh) 2022-07-01
ES2877409T3 (es) 2021-11-16
US20240100175A1 (en) 2024-03-28
US20180200377A1 (en) 2018-07-19
ZA201707464B (en) 2021-05-26
JP2023025151A (ja) 2023-02-21
CA2987322A1 (en) 2017-02-16
EP3334500B1 (en) 2021-04-07
KR20180033513A (ko) 2018-04-03
CN108135881B (zh) 2020-11-13
CN108135881A (zh) 2018-06-08
CN112263683A (zh) 2021-01-26
HK1250634A1 (zh) 2019-01-11
EP3334500A4 (en) 2019-04-03
CA2987322C (en) 2020-02-11

Similar Documents

Publication Publication Date Title
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
PH12016501411B1 (en) Bifunctional cytotoxic agents
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
MX2017010102A (es) Conjugado farmaco citotoxico-ligando, metodo de preparacion del mismo, y sus aplicaciones.
NZ737471A (en) Hydrophilic linkers for conjugation
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MY186977A (en) Tetrasubstituted alkene compounds and their use
MY178680A (en) Hydrogel prodrugs
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2017002600A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
EP3583218A4 (en) TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
PH12016501414B1 (en) Long-acting insulin and use thereof
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
PH12016501841A1 (en) Immunosuppressant formulation
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
EP3411382A4 (en) CONJUGATED DRUG-ANTI-EGFR ANTIBODY
GB2578975B (en) Use of miR-21 in preparation of drugs for treating intrauterine adhesion.
PH12017501930A1 (en) Calicheamicin contructs and methods of use